SCHEMBL766555

SCHEMBL766555

Cc1ccc(S(=O)(=O)OC[C@H]2O[C@@H](n3cc(C)c(=O)[nH]c3=O)CC2O)cc1

nearest known ligand 0.63

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
TYMS P04818 1/20 0.60
POLB P06746 1/20 0.59
TK1 P04183 3/20 0.56
BCHE P06276 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11881949 1.00 TYMS (0.60) TYMSPOLBTK1BCHE
SCHEMBL2786473 1.00 TYMS (0.60) TYMSPOLBTK1BCHE
SCHEMBL11876308 1.00 TYMS (0.60) TYMSPOLBTK1BCHE
SCHEMBL11876295 1.00 TYMS (0.60) TYMSPOLBTK1BCHE
SCHEMBL18670758 0.91 TK1 (0.61) TYMSPOLBTK1BCHE
SCHEMBL22498847 0.91 LMNA (0.61) TYMSPOLB
SCHEMBL9644079 0.91 TYMS (0.58) TYMSTK1
SCHEMBL9644073 0.91 TYMS (0.58) TYMSTK1
SCHEMBL9947618 0.91 TYMS (0.61) TYMSPOLBTK1BCHE
SCHEMBL20109714 0.88 POLB (0.63) TYMSPOLBTK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230052551-A1 FLUORESCENT PROBE FOR DETECTION OF ENPP ACTIVITY THE UNIVERSITY OF TOKYO (JP) 2023-02-16 US disclosed
EP-3981778-A1 FLUORESCENT PROBE FOR DETECTION OF ENPP ACTIVITY The University of Tokyo (JP) 2022-04-13 EP disclosed
WO-2020246616-A1 FLUORESCENT PROBE FOR DETECTION OF ENPP ACTIVITY 国立大学法人 東京大学 2020-12-10 WO disclosed
US-9533049-B2 Method for preparing nanoparticles based on functional amphiphilic molecules or macromolecules, and the use thereof UNIVERSITE D'AIX-MARSEILLE (FR) 2017-01-03 US disclosed
EP-2435031-B1 Functional amphiphilic molecule or macromolecule formulations with multiple compartments UNIV BORDEAUX (FR) 2015-09-16 EP disclosed
US-9050268-B2 Functional amphipilic molecule or macromolecule formulations with multiple compartments UNIVERSITE D'AIX-MARSEILLE (FR) 2015-06-09 US disclosed
US-20140308343-A1 METHOD FOR PREPARING NANOPARTICLES BASED ON FUNCTIONAL AMPHIPHILIC MOLECULES OR MACROMOLECULES, AND THE USE THEREOF UNIVERSITE VICTOR SEGALEN BORDEAUX 2 (FR) 2014-10-16 US disclosed
US-20120070505-A1 FUNCTIONAL AMPHIPILIC MOLECULE OR MACROMOLECULE FORMULATIONS WITH MULTIPLE COMPARTMENTS UNIVERSITE DE LA MEDITERRANEE (FR) 2012-03-22 US disclosed
US-20120070505-A1 FUNCTIONAL AMPHIPILIC MOLECULE OR MACROMOLECULE FORMULATIONS WITH MULTIPLE COMPARTMENTS UNIVERSITE DE LA MEDITERRANEE (FR) 2012-03-22 US disclosed
US-20110104754-A1 CELL CULTURE MEDIUM GENETIX LIMITED 2011-05-05 US disclosed
US-5306618-A Using xanthene dye reporter labeled DNA fragments E. I. DU PONT DE NEMOURS AND COMPANY (US) 1994-04-26 US disclosed
EP-0586520-A1 BACKBONE MODIFIED OLIGONUCLEOTIDE ANALOGS ISIS PHARMACEUTICALS, INC. (US) 1994-03-16 EP disclosed
EP-0586570-A1 BACKBONE MODIFIED OLIGONUCLEOTIDE ANALOGUES ISIS PHARMACEUTICALS, INC. (US) 1994-03-16 EP disclosed
US-5242796-A Fluorescent xanthene dye E. I. DU PONT DE NEMOURS AND COMPANY (US) 1993-09-07 US disclosed
EP-0541722-A1 COMPOUNDS AND METHODS FOR INHIBITING GENE EXPRESSION. STERLING WINTHROP INC (US) 1993-05-19 EP disclosed
WO-1992020822-A1 BACKBONE MODIFIED OLIGONUCLEOTIDE ANALOGUES ISIS PHARMACEUTICALS, INC. (US) 1992-11-26 WO disclosed
WO-1992020823-A1 BACKBONE MODIFIED OLIGONUCLEOTIDE ANALOGS ISIS PHARMACEUTICALS, INC. (US) 1992-11-26 WO disclosed
WO-1992002534-A2 COMPOUNDS AND METHODS FOR INHIBITING GENE EXPRESSION STERLING DRUG, INC. (US) 1992-02-20 WO disclosed
US-4956346-A URIDINE DERIVATIVES AS VIRICIDES HOFFMANN-LA ROCHE INC. (US) 1990-09-11 US disclosed
US-4886785-A VIRICIDES, HERPES SIMPLEX HOFFMANN-LA ROCHE INC. (US) 1989-12-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140308343-A1 METHOD FOR PREPARING NANOPARTICLES BASED ON FUNCTIONAL AMPHIPHILIC MOLECULES OR MACROMOLECULES, AND THE USE THEREOF CETP, PCTP, ABCB4 TYMS 3001/4885POLB 2015/4885TK1 1590/4885
US-20120070505-A1 FUNCTIONAL AMPHIPILIC MOLECULE OR MACROMOLECULE FORMULATIONS WITH MULTIPLE COMPARTMENTS ANXA2, SLC47A2, ABCB4 TYMS 3407/4885POLB 1851/4885TK1 1011/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.